Successful Independent Study of the NanoVibronix UroShield® Device Published in the Australian and New Zealand Continence Journal
Portfolio Pulse from
NanoVibronix, Inc. announced the publication of an independent study in The Australian and New Zealand Continence Journal, highlighting the effectiveness of its UroShield® device in preventing catheter-associated urinary tract infections.
March 14, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NanoVibronix's UroShield® device was featured in an independent study published in a reputable journal, demonstrating its effectiveness in preventing catheter-associated urinary tract infections. This positive validation could enhance the product's market adoption.
The publication of an independent study in a reputable journal provides external validation of the UroShield® device's effectiveness. This could lead to increased adoption and sales, positively impacting NanoVibronix's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100